HAII is one of the most innovative digital therapeutics companies in South Korea. HAII was founded in 2016. HAII has signed a 5-year exclusive License-OUT contract with Eisai.Co.LTD for a cognitive function improvement service APP in 2019. In 2021, for the first time in Korea HAII obtained approval from the Ministry of Food and Drug Safety for a pivotal clinical trial for DTx of GAD. In February 2022, HAII proceeded to supply mental health screening app with KMI, the largest medical checkup clinic in Korea, and accumulated data for more than 160,000 people during the year. In the same year, HAII raised about $5.7M in Series B investment. In 2023, data applied with digital biomarkers such as HRV (Heart Rate Viability) has been accumulated for about 3,000 people from Jan. to March. In 2023, HAII also founded the first oversea corporation in Boston to advance into the United States.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
SEOUL
Company HQ Country:
Korea, Republic of
Year Founded:
2016
Main Therapeutic Focus:
Digital Health
Lead Product in Development:
AnzeiLax, DTX for Generalized Anxiety Disorder and Depression by applying a digital biomarker (e.g. HRV) applicable to the patient's smartphone without any other devices such as a smart watch or VR gears
Development Phase of Primary Product:
Phase IV
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Three
Speaker
